Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healios KK Ord Shs HLOSF

Healthcare Biotechnology
Healios KK is a Japan-based company mainly engaged in business in the somatic stem cell regenerative medicine field and in the iPSC regenerative medicine field, which involves research, development and manufacture of regenerative medicine products (iPSC regenerative medicines) utilizing technologies related to induced pluripotent stem cells (iPS cells, iPSCs). The somatic stem cell regenerative medicine field develops and markets cell therapy drugs for acute stroke and acute respiratory distress syndrome using MultiStem, a somatic stem cell product for which the Company holds patent and patent licensing rights. The iPSC regenerative medicines include the creation of universal donor cells (UD), next-generation iPSCs that reduce the risk of immune rejection regardless of human leukocyte antigen (HLA) type using gene editing technology.


PINL:HLOSF - Post by User

Healios KK Ord Shs > HudBay plans to buy them out......
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by ama21968on Nov 07, 2010 2:07pm
217 Views
Post# 17670613

RE: RE: RE: HudBay plans to buy them out......

RE: RE: RE: HudBay plans to buy them out......

I see J.D.M as a potential hazard on the way down the road. so bad, I hate to say that, but it is your God feeling ....
however, I guess PNP / Halo had made somewhat  "deals " with J.D.M behind the door prior to recent PP, for example: J.D.M had a 5 cents PP was cancelled in the summer time before AGM and SC....

I also found PNP has increased its holding (from 10% to 17.6%) during this summer time,,, (from open market or J.D.M ?)

You check Ink research, it shows J.D.M was doing internal accounts consolidations; what does that mean usually?

PNP and/or  First Canadian Capital will be the man to solve this problem,  I hope... they are financially strong ...

So I said, from T.Astandpoint.  I am anticipating daily volume increases with large amount "cross trade" or "Shooting star " pattern to DOWN side ; "Trading errors" and so on .... These are very positive signs you should keep eyes on... otherwise  Halo is a sick dog forever....

ALWAYS SOMEONE KNEW SOMETHING YOU DO NOT!!!
Management is Key 
Trading is Tech
Manipulation is Art

Keep your mind open 

GLTA

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities